Amgen Innovator Series

September 1, 2016

Alejandro Tocigl
CEO, Miraculous

Miroculus provides decentralized, affordable, non-invasive molecular diagnostics by leveraging blood circulating microRNAs and a proprietary digital microfluidics technology. Their first application is a test for gastric cancer in symptomatic patients, a US$3B market. The test’s high negative predictive value will enable physicians to safely avoid endoscopy for cancer-free patients, increasing cancer detection rate while reducing the total healthcare cost.

Sponsored by: